Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers.

Guiu S, Mollevi C, Charon-Barra C, Boissière F, Crapez E, Chartron E, Lamy PJ, Gutowski M, Bourgier C, Romieu G, Simony-Lafontaine J, Jacot W.

Br J Cancer. 2018 Jun 8. doi: 10.1038/s41416-018-0142-6. [Epub ahead of print]

PMID:
29880907
2.

Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort.

Gobbini E, Ezzalfani M, Dieras V, Bachelot T, Brain E, Debled M, Jacot W, Mouret-Reynier MA, Goncalves A, Dalenc F, Patsouris A, Ferrero JM, Levy C, Lorgis V, Vanlemmens L, Lefeuvre-Plesse C, Mathoulin-Pelissier S, Petit T, Uwer L, Jouannaud C, Leheurteur M, Lacroix-Triki M, Cleaud AL, Robain M, Courtinard C, Cailliot C, Perol D, Delaloge S.

Eur J Cancer. 2018 Jun;96:17-24. doi: 10.1016/j.ejca.2018.03.015. Epub 2018 Apr 13.

PMID:
29660596
3.

Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.

Jacquet E, Lardy-Cléaud A, Pistilli B, Franck S, Cottu P, Delaloge S, Debled M, Vanlemmens L, Leheurteur M, Guizard AV, Laborde L, Uwer L, Jacot W, Berchery D, Desmoulins I, Ferrero JM, Perrocheau G, Courtinard C, Brain E, Chabaud S, Robain M, Bachelot T.

Eur J Cancer. 2018 May;95:93-101. doi: 10.1016/j.ejca.2018.03.013. Epub 2018 Apr 11.

PMID:
29655061
4.

Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer.

Darlix A, Griguolo G, Thezenas S, Kantelhardt E, Thomssen C, Dieci MV, Miglietta F, Conte P, Braccini AL, Ferrero JM, Bailleux C, Jacot W, Guarneri V.

J Neurooncol. 2018 Jun;138(2):369-382. doi: 10.1007/s11060-018-2805-9. Epub 2018 Feb 27.

PMID:
29488184
5.

Serum Vitamin D Levels Affect Pathologic Complete Response in Patients Undergoing Neoadjuvant Systemic Therapy for Operable Breast Cancer.

Chiba A, Raman R, Thomas A, Lamy PJ, Viala M, Pouderoux S, Mott SL, Schroeder MC, Thezenas S, Jacot W.

Clin Breast Cancer. 2018 Apr;18(2):144-149. doi: 10.1016/j.clbc.2017.12.001. Epub 2017 Dec 11.

PMID:
29290565
6.

External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience.

Griguolo G, Jacot W, Kantelhardt E, Dieci MV, Bourgier C, Thomssen C, Bailleux C, Miglietta F, Braccini AL, Conte P, Ferrero JM, Guarneri V, Darlix A.

Breast. 2018 Feb;37:36-41. doi: 10.1016/j.breast.2017.10.006. Epub 2017 Oct 23.

PMID:
29073498
7.

Management and cost analysis of cancer patients treated with G-CSF: a cohort study based on the French national healthcare insurance database.

Tilleul P, Jacot W, Emery C, Lafuma A, Gourmelen J.

J Med Econ. 2017 Dec;20(12):1261-1267. doi: 10.1080/13696998.2017.1366324. Epub 2017 Sep 4.

PMID:
28795868
8.

Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2- pN0 early breast cancers.

Viala M, Alexandre M, Thezenas S, Lamy PJ, Maran-Gonzalez A, Gutowski M, Colombo PE, Romieu G, Jacot W, Guiu S.

Breast Cancer Res Treat. 2017 Oct;165(3):611-621. doi: 10.1007/s10549-017-4373-7. Epub 2017 Jul 6.

PMID:
28685212
9.

[Erratum to: "Breast cancer screening: On our way to the future" [Bull. Cancer 103 (2016) 753-763]].

Delaloge S, Bachelot T, Bidard FC, Espie M, Brain E, Bonnefoi H, Gligorov J, Dalenc F, Hardy-Bessard AC, Azria D, Jacquin JP, Lemonnier J, Jacot W, Goncalves A, Coutant C, Ganem G, Petit T, Penault-Llorca F, Debled M, Campone M, Levy C, Coudert B, Lortholary A, Venat-Bouvet L, Grenier J, Bourgeois H, Asselain B, Arvis J, Castro M, Tardivon A, Cox DG, Arveux P, Balleyguier C, André F, Rouzier R; Intergroupe national de recherche sur le cancer du sein Unicancer (UCBG).

Bull Cancer. 2016 Nov;103(11):951-952. doi: 10.1016/j.bulcan.2016.10.009. Epub 2016 Oct 28. French. No abstract available.

PMID:
28029350
10.

French law: what about a reasoned reimbursement of serum vitamin D assays?

Souberbielle JC, Benhamou CL, Cortet B, Rousière M, Roux C, Abitbol V, Annweiler C, Audran M, Bacchetta J, Bataille P, Beauchet O, Bardet R, Benachi A, Berenbaum F, Blain H, Borson-Chazot F, Breuil V, Briot K, Brunet P, Carel JC, Caron P, Chabre O, Chanson P, Chapurlat R, Cochat P, Coutant R, Christin-Maitre S, Cohen-Solal M, Combe C, Cormier C, Courbebaisse M, Debrus G, Delemer B, Deschenes G, Duquenne M, Duval G, Fardellone P, Fouque D, Friedlander G, Gauvain JB, Groussin L, Guggenbuhl P, Houillier P, Hannedouche T, Jacot W, Javier RM, Jean G, Jeandel C, Joly D, Kamenicky P, Knebelmann B, Lafage-Proust MH, LeBouc Y, Legrand E, Levy-Weil F, Linglart A, Machet L, Maheu E, Mallet E, Marcelli C, Marès P, Mariat C, Maruani G, Maugars Y, Montagnon F, Moulin B, Orcel P, Partouche H, Personne V, Pierrot-Deseilligny C, Polak M, Pouteil-Noble C, Prié D, Raynaud-Simon A, Rolland Y, Sadoul JL, Salle B, Sault C, Schott AM, Sermet-Gaudelus I, Soubrier M, Tack I, Thervet E, Tostivint I, Touraine P, Tremollières F, Urena-Torres P, Viard JP, Wemeau JL, Weryha G, Winer N, Young J, Thomas T.

Geriatr Psychol Neuropsychiatr Vieil. 2016 Dec 1;14(4):377-382. Review.

PMID:
27818369
11.

Breast cancer and screening in persons with an intellectual disability living in institutions in France.

Trétarre B, Bourgarel S, Stoebner-Delbarre A, Jacot W, Bessaoud F, Satge D.

J Intellect Disabil Res. 2017 Mar;61(3):266-278. doi: 10.1111/jir.12336. Epub 2016 Sep 13.

PMID:
27624823
12.

[Breast cancer screening: On our way to the future].

Delaloge S, Bachelot T, Bidard FC, Espie M, Brain E, Bonnefoi H, Gligorov J, Dalenc F, Hardy-Bessard AC, Azria D, Jacquin JP, Lemonnier J, Jacot W, Goncalves A, Coutant C, Ganem G, Petit T, Penault-Lorca F, Debled M, Campone M, Levy C, Coudert B, Lortholary A, Venat-Bouvet L, Grenier J, Bourgeois H, Asselain B, Arvis J, Castro M, Tardivon A, Cox DG, Arveux P, Balleyguier C, André F, Rouzier R; Intergroupe national de recherche sur le cancer du sein Unicancer (UCBG).

Bull Cancer. 2016 Sep;103(9):753-63. doi: 10.1016/j.bulcan.2016.06.005. Epub 2016 Jul 26. Review. French.

PMID:
27473920
13.

Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases?

Darlix A, Lamy PJ, Lopez-Crapez E, Braccini AL, Firmin N, Romieu G, Thézenas S, Jacot W.

Int J Cancer. 2016 Nov 15;139(10):2299-311. doi: 10.1002/ijc.30290. Epub 2016 Aug 6.

14.

Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.

Delaloge S, Pérol D, Courtinard C, Brain E, Asselain B, Bachelot T, Debled M, Dieras V, Campone M, Levy C, Jacot W, Lorgis V, Veyret C, Dalenc F, Ferrero JM, Uwer L, Kerbrat P, Goncalves A, Mouret-Reynier MA, Petit T, Jouannaud C, Vanlemmens L, Chenuc G, Guesmia T, Robain M, Cailliot C.

Ann Oncol. 2016 Sep;27(9):1725-32. doi: 10.1093/annonc/mdw260. Epub 2016 Jul 19.

PMID:
27436849
15.

Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients.

Darlix A, Lamy PJ, Lopez-Crapez E, Braccini AL, Firmin N, Romieu G, Thezenas S, Jacot W.

BMC Cancer. 2016 Jul 7;16:428. doi: 10.1186/s12885-016-2448-1.

16.

Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases.

Jacot W, Pons E, Frenel JS, Guiu S, Levy C, Heudel PE, Bachelot T, D'Hondt V, Darlix A, Firmin N, Romieu G, Thezenas S, Dalenc F.

Breast Cancer Res Treat. 2016 Jun;157(2):307-318. doi: 10.1007/s10549-016-3828-6. Epub 2016 May 11.

PMID:
27167986
17.

Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: a randomized phase III study.

Jacot W, Firmin N, Roca L, Topart D, Gallet S, Durigova A, Mirr S, Abach L, Pouderoux S, D'Hondt V, Bleuse JP, Lamy PJ, Romieu G.

Ann Oncol. 2016 Jul;27(7):1235-41. doi: 10.1093/annonc/mdw145. Epub 2016 Mar 30.

PMID:
27029707
18.

High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers.

Jacot W, Mollevi C, Fina F, Lopez-Crapez E, Martin PM, Colombo PE, Bibeau F, Romieu G, Lamy PJ.

BMC Cancer. 2015 Dec 18;15:986. doi: 10.1186/s12885-015-1977-3.

19.

[Granulocyte- colony stimulating factor (G-CSF) use in clinical practice in patients receiving chemotherapy for breast cancer: The Opaline Study].

Jacot W, Antoine EC, Hacini M, Giron C, Rivière A, Moureau-Zabotto L, Cassin D, Yazbek G, Orfeuvre H, Sakek N, Diab R, Bastit L, Mille D, Azria D.

Bull Cancer. 2015 Dec;102(12):979-92. doi: 10.1016/j.bulcan.2015.09.004. Epub 2015 Nov 17. French.

PMID:
26597475
20.

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).

Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso MJ, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E, Debled M, Delaloge S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove C, MacGrogan G, Michiels S, Negreiros I, Offersen BV, Penault Llorca F, Pruneri G, Roche H, Russell NS, Schmitt F, Servent V, Thürlimann B, Untch M, van der Hage JA, van Tienhoven G, Wildiers H, Yarnold J, Bonnetain F, Mathoulin-Pélissier S, Bellera C, Dabakuyo-Yonli TS.

Ann Oncol. 2015 Dec;26(12):2505-6. doi: 10.1093/annonc/mdv478. Epub 2015 Oct 13. No abstract available.

PMID:
26467471
21.

Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study.

Dell'Ova M, De Maio E, Guiu S, Roca L, Dalenc F, Durigova A, Pinguet F, Bekhtari K, Jacot W, Pouderoux S.

BMC Cancer. 2015 Oct 8;15:659. doi: 10.1186/s12885-015-1673-3.

22.

Oncoplastic Resection of Breast Cancers Located in the Lower-Inner or Lower-Outer Quadrant with the Modified McKissock Mammaplasty Technique.

Colombo PE, Lefèvre M, Delmond L, Traore D, Jacot W, Mourregot A, Gutowski M, Bertrand MM, Rouanet P.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S486-94. doi: 10.1245/s10434-015-4727-5. Epub 2015 Jul 16.

PMID:
26178763
23.

Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study.

Gligorov J, Pivot XB, Jacot W, Naman HL, Spaeth D, Misset JL, Largillier R, Sautiere JL, de Roquancourt A, Pomel C, Rouanet P, Rouzier R, Penault-Llorca FM; Francilian Breast Intergroup.

Oncologist. 2015 Aug;20(8):873-9. doi: 10.1634/theoncologist.2014-0467. Epub 2015 Jun 25.

24.

Frequent expression of PD-L1 on circulating breast cancer cells.

Mazel M, Jacot W, Pantel K, Bartkowiak K, Topart D, Cayrefourcq L, Rossille D, Maudelonde T, Fest T, Alix-Panabières C.

Mol Oncol. 2015 Nov;9(9):1773-82. doi: 10.1016/j.molonc.2015.05.009. Epub 2015 Jun 9.

25.

Resolving quandaries: basaloid adenoid cystic carcinoma or breast cylindroma? The role of massively parallel sequencing.

Fusco N, Colombo PE, Martelotto LG, De Filippo MR, Piscuoglio S, Ng CK, Lim RS, Jacot W, Vincent-Salomon A, Reis-Filho JS, Weigelt B.

Histopathology. 2016 Jan;68(2):262-71. doi: 10.1111/his.12735. Epub 2015 Jun 29.

26.

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.

Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso MJ, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E, Debled M, Delaloge S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove C, MacGrogan G, Michiels S, Negreiros I, Offersen BV, Penault Llorca F, Pruneri G, Roche H, Russell NS, Schmitt F, Servent V, Thürlimann B, Untch M, van der Hage JA, van Tienhoven G, Wildiers H, Yarnold J, Bonnetain F, Mathoulin-Pélissier S, Bellera C, Dabakuyo-Yonli TS; Definition for the Assessment of Time-to-event Endpoints in Cancer Trials Initiative.

Ann Oncol. 2015 May;26(5):873-9. doi: 10.1093/annonc/mdv106. Epub 2015 Feb 27. Review. Erratum in: Ann Oncol. 2015 Dec;26(12):2505-6.

PMID:
25725046
27.

Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyond BRCA1/2 mutations?

Jacot W, Theillet C, Guiu S, Lamy PJ.

Future Oncol. 2015;11(4):557-9. doi: 10.2217/fon.14.268. No abstract available.

PMID:
25686112
28.

Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study.

Bonnefoi H, Jacot W, Saghatchian M, Moldovan C, Venat-Bouvet L, Zaman K, Matos E, Petit T, Bodmer A, Quenel-Tueux N, Chakiba C, Vuylsteke P, Jerusalem G, Brain E, Tredan O, Messina CG, Slaets L, Cameron D.

Ann Oncol. 2015 Feb;26(2):325-32. doi: 10.1093/annonc/mdu551. Epub 2014 Dec 1.

29.

Invasive lobular breast cancer and its variants: how special are they for systemic therapy decisions?

Guiu S, Wolfer A, Jacot W, Fumoleau P, Romieu G, Bonnetain F, Fiche M.

Crit Rev Oncol Hematol. 2014 Dec;92(3):235-57. doi: 10.1016/j.critrevonc.2014.07.003. Epub 2014 Jul 30. Review.

PMID:
25129506
30.

[Weakening osteopathies, chronic kidney disease, malabsorption, biological anomalies of calium/phosphorus metabolism: appropriate indications for a reasoned reimbursment of serum vitamin D measurement].

Souberbielle JC, Benhamou CL, Cortet B, Rousière M, Roux C, Abitbol V, Annweiler C, Audran M, Bacchetta J, Bataille P, Beauchet O, Bardet R, Benachi A, Berenbaum F, Blain H, Borson-Chazot F, Breuil V, Briot K, Brunet P, Carel JC, Caron P, Chabre O, Chanson P, Chapurlat R, Cochat P, Coutant R, Christin-Maitre S, Cohen-Solal M, Combe C, Cormier C, Courbebaisse M, Debrus G, Delemer B, Deschenes G, Duquenne M, Fardellone P, Fouque D, Friedlander G, Gauvain JB, Groussin L, Guggenbuhl P, Houillier P, Hannedouche T, Jacot W, Javier RM, Jean G, Jeandel C, Joly D, Kamenicky P, Knebelmann B, Lafage-Proust MH, LeBouc Y, Legrand E, Levy-Weil F, Linglart A, Machet L, Maheu E, Mallet E, Marcelli C, Marès P, Mariat C, Maruani G, Maugars Y, Montagnon F, Moulin B, Orcel P, Partouche H, Personne V, Pierrot-Deseilligny C, Polak M, Pouteil-Noble C, Prié D, Raynaud-Simon A, Rolland Y, Sadoul JL, Salle B, Sault C, Schott AM, Sermet-Gaudelus I, Soubrier M, Tack I, Thervet É, Tostivint I, Touraine P, Tremollières F, Urena-Torres P, Viard JP, Wemeau JL, Weryha G, Winer N, Young J, Thomas T.

Ann Biol Clin (Paris). 2014 Jul-Aug;72(4):385-9. doi: 10.1684/abc.2014.0972. French. No abstract available.

31.

Iron homeostasis and anemia markers in early breast cancer.

Lamy PJ, Durigova A, Jacot W.

Clin Chim Acta. 2014 Jul 1;434:34-40. doi: 10.1016/j.cca.2014.04.011. Epub 2014 Apr 24. Review.

PMID:
24768787
32.

36th San Antonio Breast Cancer Symposium: focus on clinical trial results.

Jacot W.

Future Oncol. 2014 Mar;10(4):511-3. doi: 10.2217/fon.14.11.

33.

Age and stage at diagnosis: a hospital series of 11 women with intellectual disability and breast carcinoma.

Satgé D, Sauleau EA, Jacot W, Raffi F, Azéma B, Bouyat JC, El Hage Assaf N.

BMC Cancer. 2014 Mar 4;14:150. doi: 10.1186/1471-2407-14-150.

34.

Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision-making for early breast cancer.

Saadoun H, Lamy PJ, Thezenas S, Pouderoux S, Bibeau F, Montels F, Romieu G, Colombo PE, Gutowski M, Jacot W.

Future Oncol. 2014 Feb;10(2):195-209. doi: 10.2217/fon.13.177.

PMID:
24490606
35.

[HAS report on vitamin D measurement: don't go from an extreme situation to another as extreme situation].

Souberbielle JC, Benhamou CL, Cortet B, Rousière M, Roux C, Abitbol V, Audran M, Bachetta J, Beauchet O, Blain H, Breuil V, Briot K, Brunet P, Chanson P, Cormier C, Courbebaisse M, Fardellone P, Fouque D, Friedlander G, Gauvain JB, Groussin L, Houillier P, Jacot W, Jean G, Kamenicky P, Lafage-Proust MH, Legrand E, Levy-Weil F, Linglart A, Mallet E, Marcelli C, Maruani G, Montagnon F, Personne V, Prié D, Raynaud-Simon A, Rolland Y, Salle B, Sault C, Schott AM, Thervet E, Urena-Torres P, Viard JP, Weryha G, Pierrot-Deseilligny C, Young J, Thomas T.

Presse Med. 2014 Jan;43(1):5-8. doi: 10.1016/j.lpm.2013.12.005. French. No abstract available.

PMID:
24439118
36.

Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse.

du Manoir S, Orsetti B, Bras-Gonçalves R, Nguyen TT, Lasorsa L, Boissière F, Massemin B, Colombo PE, Bibeau F, Jacot W, Theillet C.

Mol Oncol. 2014 Mar;8(2):431-43. doi: 10.1016/j.molonc.2013.11.010. Epub 2013 Dec 19.

37.

Serum Matrix Metalloproteinase-7 is an independent prognostic biomarker in advanced bladder cancer.

El Demery M, Demirdjian-Sarkissian G, Thezenas S, Jacot W, Laghzali Y, Darbouret B, Culine S, Rebillard X, Lamy PJ.

Clin Transl Med. 2014 Oct 28;3:31. doi: 10.1186/s40169-014-0031-4. eCollection 2014.

38.

BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer.

Jacot W, Thezenas S, Senal R, Viglianti C, Laberenne AC, Lopez-Crapez E, Bibeau F, Bleuse JP, Romieu G, Lamy PJ.

BMC Cancer. 2013 Nov 5;13:523. doi: 10.1186/1471-2407-13-523.

39.

[Vitamin D and breast cancer: physiopathology, biological and clinical implications].

Firmin N, Lamy PJ, Romieu G, Jacot W.

Bull Cancer. 2014 Mar;101(3):266-82. doi: 10.1684/bdc.2013.1826. Review. French.

PMID:
24103818
40.

Adapted physical activity and diet (APAD) during adjuvant breast cancer therapy: design and implementation of a prospective randomized controlled trial.

Carayol M, Romieu G, Bleuse JP, Senesse P, Gourgou-Bourgade S, Sari C, Jacot W, Sancho-Garnier H, Janiszewski C, Launay S, Cousson-Gélie F, Ninot G.

Contemp Clin Trials. 2013 Nov;36(2):531-43. doi: 10.1016/j.cct.2013.09.016. Epub 2013 Oct 4.

PMID:
24096188
41.

Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.

Braccini AL, Azria D, Thezenas S, Romieu G, Ferrero JM, Jacot W.

Breast. 2013 Oct;22(5):993-8. doi: 10.1016/j.breast.2013.05.011. Epub 2013 Jul 3.

PMID:
23831232
42.

Anemia and iron biomarkers in patients with early breast cancer. Diagnostic value of hepcidin and soluble transferrin receptor quantification.

Durigova A, Lamy PJ, Thezenas S, Pouderoux S, Montels F, Romieu G, Gutowski M, Jacot W.

Clin Chem Lab Med. 2013 Sep;51(9):1833-41. doi: 10.1515/cclm-2013-0031.

PMID:
23787470
43.

The HER2 amplicon in breast cancer: Topoisomerase IIA and beyond.

Jacot W, Fiche M, Zaman K, Wolfer A, Lamy PJ.

Biochim Biophys Acta. 2013 Aug;1836(1):146-57. doi: 10.1016/j.bbcan.2013.04.004. Epub 2013 Apr 26. Review.

PMID:
23628726
44.

Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial.

Robertson JF, Ferrero JM, Bourgeois H, Kennecke H, de Boer RH, Jacot W, McGreivy J, Suzuki S, Zhu M, McCaffery I, Loh E, Gansert JL, Kaufman PA.

Lancet Oncol. 2013 Mar;14(3):228-35. doi: 10.1016/S1470-2045(13)70026-3. Epub 2013 Feb 13.

PMID:
23414585
45.

Comparative performances of prognostic indexes for breast cancer patients presenting with brain metastases.

Braccini AL, Azria D, Thezenas S, Romieu G, Ferreri JM, Jacot W.

BMC Cancer. 2013 Feb 8;13:70. doi: 10.1186/1471-2407-13-70.

46.

Re: clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review.

Lamy PJ, Martin PM, Romieu G, Jacot W.

J Natl Cancer Inst. 2013 Jan 16;105(2):149. doi: 10.1093/jnci/djs492. Epub 2012 Dec 14. No abstract available.

PMID:
23243205
47.

TOP2A amplification in breast cancer in the absence of that of HER-2: myth or reality?

Lamy PJ, Jacot W.

Oncologist. 2012;17(12):e60-1. doi: 10.1634/theoncologist.2011-0430. Epub 2012 Jul 20. No abstract available.

48.

[Iron metabolism in breast cancer: knowledge and future].

Durigova A, Jacot W, Pouderoux S, Roques S, Montels F, Lamy PJ.

Ann Biol Clin (Paris). 2012 Jul-Aug;70(4):387-96. French.

49.

[How to treat brain metastasis in 2012?].

Braccini AL, Azria D, Mazeron JJ, Mornex F, Jacot W, Metellus P, Tallet A.

Cancer Radiother. 2012 Jul-Aug;16(4):309-14. doi: 10.1016/j.canrad.2012.03.010. Epub 2012 Jul 10. Review. French.

PMID:
22784591
50.

Severe peritonitis induced by methotrexate during treatment of persistent gestational trophoblastic disease.

Zimmermann S, Zaman K, Wolfer A, Jacot W.

Oncologist. 2012;17(8):e18-20. doi: 10.1634/theoncologist.2012-0146. Epub 2012 Jun 1. No abstract available.

Supplemental Content

Support Center